In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on KalVista Pharmaceuticals, with a price target of $30.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Stacy Ku has given her Buy rating due to a combination of factors surrounding KalVista Pharmaceuticals’ recent developments and market potential. The company is in the early stages of launching Ekterly, an oral treatment for acute hereditary angioedema (HAE), which is expected to generate significant patient interest due to its convenience and efficacy comparable to existing treatments. Although initial sales are projected to be minimal, the focus is on clinician engagement and securing access and reimbursement, which are crucial for long-term success.
KalVista’s strategy includes a free bridge program to facilitate access and medical exemptions for reimbursement, which should help drive patient adoption. The company’s projections indicate that treating a small percentage of diagnosed HAE patients could lead to substantial revenue, with expectations of Ekterly achieving $750 million in sales and capturing a significant market share. The anticipated growth in on-demand usage and the first-mover advantage further support the optimistic outlook, making KalVista an attractive investment opportunity.
According to TipRanks, Ku is a 4-star analyst with an average return of 6.6% and a 59.22% success rate. Ku covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, KalVista Pharmaceuticals, and LENZ Therapeutics.